Cerus(US:CERS)2025-07-09 13:11Financial Performance & Outlook - Cerus achieved positive non-GAAP adjusted EBITDA for Q4 and full year 2024 [9] - The company anticipates product revenue growth of 8% to 11% year-over-year in 2025 [9] - Cerus is committed to sustaining positive adjusted EBITDA for fiscal year 2025 [9] - GAAP net loss attributable to Cerus improved by over 40% in 2024 compared to 2023 [9] - In 2024, Cerus achieved 15% topline growth due to strong team performance and blood center partnerships [10] Market & Product Expansion - Cerus is focused on the continued global expansion of its platelet franchise [9] - The company expects increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the US [9] - The global addressable market for INTERCEPT products is currently $1.3 billion and is expected to grow to over $1.5 billion in the next 5-7 years [16] - The U S addressable market is $150 million and is expected to grow to over $200 million in the next 5-7 years [16] Technology & Impact - Cumulative kit sales for over 16 million INTERCEPT treated doses of platelets & plasma [5]